Drug Profile
BRL 26830A
Alternative Names: BRL 26830Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Anorectics; Antihyperlipidaemics; Benzoic acids
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus; Hyperlipidaemia; Obesity